Zulimont M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, which play a key role in the inflammatory process associated with asthma and allergic rhinitis. The synergistic action of these two agents provides comprehensive relief from allergic symptoms by targeting different pathways involved in the allergic response. Zulimont M is particularly useful in patients who require both antihistaminic and leukotriene receptor antagonist therapy for optimal symptom control. The tablet is generally well tolerated, with a low incidence of adverse effects such as headache, fatigue, or gastrointestinal discomfort. It is recommended to be taken once daily, preferably in the evening, with or without food, as directed by a healthcare professional. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision in pediatric and elderly populations.